Research reinforces Sabinsa curcumin ingredient's oral health benefits

Published: 26-Jan-2021

Featured companies: Sabinsa

The research builds on a previous trial investigating the ingredient’s efficacy against oral leukoplakia

Research has recently been published investigating Sabinsa’s Curcumin C3 Reduct ingredient in oral care applications.

Tetrahydrocurcuminoids (THCs) are among the major active metabolites formed on oral curcuminoids ingestion. Sabinsa’s Curcumin C3 Reduct is a self-affirmed GRAS ingredient entirely composed of these reductive metabolites.

In a recent clinical trial involving 30 canker sore patients and 29 patients with gingivitis, treatment with two 100 mg Curcumin C3 Reduct chewable tablets daily over a three week period showed positive results.

At the end of the study, all canker sore patients had recovered totally. The efficacy of C3 Reduct in gingivitis was evaluated by several parameters including gingival index score, bleeding and inflammation. C3 Reduct treatment led to abatement of pain, numbness, ulcer formation, dryness with no staining or allergic symptoms.

The results are published as a peer-reviewed paper in Evidenced-Based Complementary and Alternative Medicine ‘Efficacy and Safety of Tetrahydrocurcuminoids for the treatment of Canker Sore and Gingivitis,’ by Dr Muhammed Majeed, Shaheen Majeed, and Dr Kalyanam Nagabhushanam. ¹

A previously published independent clinical paper focused on the utility of C3 Reduct in oral leukoplakia which could ultimately progress to oral cancer in certain cases. C3 Reduct was applied as a 2% gel formulation in the affected areas inside the mouth. The researchers concluded the topically applied gel was effective in alleviating clinical symptoms.

The results, ‘Efficacy and Safety of Tetrahydrocurcuminoids in the Treatment of Oral Leukoplakia: A Pilot Study’ by Yogesh Chhaparwal et al was published in Asian Journal of Pharmaceutical Clinical Research.²

“Discovering herbal-based treatments in conditions where no satisfactory pharma therapy is readily available continues to drive our innovation,” said Dr Muhammed Majeed, Founder and Chairman of the Sami-Sabinsa Group. “It is particularly satisfying when no side effects are seen in these trials and the treatment costs are eminently affordable.”